Sommaire

Numéro précédent | Numéro suivant

• • ·Drinking ourselves into oblivion?

    Page :103

     
• • ·The sum is greater than the parts

    Page :103

     
• • ·Targeting the target: a step forward for the treatment of non-small-cell lung cancer

    Page :104-105

    Jean Yves Douillard

     
• • ·IGF-1R targeted treatment of sarcoma

    Page :105-106

    Jeffrey A Toretsky, Richard Gorlick

     
• • ·Using microRNAs to understand cancer biology

    Page :106-107

    Joanne Weidhaas

     
• • ·Hot flushes: mostly sex neutral?

    Page :107-108

    Charles L Loprinzi, Sherry L Wolf

     
• • ·Immunity unleashed in melanoma

    Page :108-109

    Michael K Erdmann

     
• • ·Cancer survival in the developing world

    Page :110-111

    Michel P Coleman

     
• • ·Patient access schemes for high-cost cancer medicines

    Page :111-112

    Steve Williamson

     
• • ·Risk of bleeding not increased by sorafenib or sunitinib

    Page :112-113

    David R Minor

    
• • ·Risk of bleeding not increased by sorafenib or sunitinib – Authors’ reply

    Page :113

    Youjin Je, Fabio AB Schutz, Toni K Choueiri

     
• • ·Lateral pelvic lymph-node dissection: still an option for cure

    Page :114

    Hideaki Yano, Brendan J Moran, Toshiaki Watanabe, Kenichi Sugihara

     
• • ·Lateral pelvic lymph-node dissection: still an option for cure – Authors’ reply

    Page :114-115

    Panagiotis Georgiou, Emile Tan, Nikolaos Gouvas, Anthony Antoniou, Gina Brown, R John Nicholls, Paris Tekkis

    
• • ·Histological subtype of gastric cancer in Japan

    Page :115-116

    Kohei Shitara, Kei Muro

     
• • ·Resection of colorectal liver metastases: only for younger patients?

    Page :116

    Derek G Power, Stuart M Lichtman

     
• • ·Appropriate feeding balances risk and quality of life

    Page :117

    Talha Burki

     
• • ·US secrecy obscures identities of carcinogenic chemicals

    Page :118-119

    Bryant Furlow

     
• • ·US oncologists fight further cuts to Medicare reimbursement

    Page :119

    Mary Beth Nierengarten

    
• • ·Know thy enemy

    Page :120

    Talha Burki

     
• • ·Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

    Page :121-128

    Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima, Kazuhiro Asami, Nobuyuki Katakami, Minoru Takada, Hiroshige Yoshioka, Kazuhiko Shibata, Shinzoh Kudoh, Eiji Shimizu, Hiroshi Saito, Shinichi Toyooka, Kazuhiko Nakagawa, Masahiro Fukuoka, for the West Japan Oncology Group

    Résumé Résumé Plan Plan   
• • ·Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort study

    Page :129-135

    David Olmos, Sophie Postel-Vinay, L Rhoda Molife, Scott H Okuno, Scott M Schuetze, M Luisa Paccagnella, Gretchen N Batzel, Donghua Yin, Kathryn Pritchard-Jones, Ian Judson, Francis P Worden, Antonio Gualberto, Michelle Scurr, Johann S de Bono, Paul Haluska

    Résumé Résumé Plan Plan  
• • ·Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis

    Page :136-146

    Tetsuya Ueda, Stefano Volinia, Hiroshi Okumura, Masayoshi Shimizu, Cristian Taccioli, Simona Rossi, Hansjuerg Alder, Chang-gong Liu, Naohide Oue, Wataru Yasui, Kazuhiro Yoshida, Hiroki Sasaki, Sachiyo Nomura, Yasuyuki Seto, Michio Kaminishi, George A Calin, Carlo M Croce

    Résumé Résumé Plan Plan   
• • ·Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial

    Page :147-154

    Jacques Irani, Laurent Salomon, Rostand Oba, Philippe Bouchard, Nicolas Mottet

    Résumé Résumé Plan Plan  
• • ·Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

    Page :155-164

    Jedd D Wolchok, Bart Neyns, Gerald Linette, Sylvie Negrier, Jose Lutzky, Luc Thomas, William Waterfield, Dirk Schadendorf, Michael Smylie, Troy Guthrie, Jean-Jacques Grob, Jason Chesney, Kevin Chin, Kun Chen, Axel Hoos, Steven J O’Day, Celeste Lebbé

    Résumé Résumé Plan Plan   
• • ·Cancer survival in Africa, Asia, and Central America: a population-based study

    Page :165-173

    Rengaswamy Sankaranarayanan, Rajaraman Swaminathan, Hermann Brenner, Kexin Chen, Kee Seng Chia, Jian Guo Chen, Stephen CK Law, Yoon-Ok Ahn, Yong Bing Xiang, Balakrishna B Yeole, Hai Rim Shin, Viswanathan Shanta, Ze Hong Woo, Nimit Martin, Yupa Sumitsawan, Hutcha Sriplung, Adolfo Ortiz Barboza, Sultan Eser, Bhagwan M Nene, Krittika Suwanrungruang, Padmavathiamma Jayalekshmi, Rajesh Dikshit, Henry Wabinga, Divina B Esteban, Adriano Laudico, Yasmin Bhurgri, Ebrima Bah, Nasser Al-Hamdan

    Résumé Résumé Plan Plan   
• • ·Ki67 in breast cancer: prognostic and predictive potential

    Page :174-183

    Rinat Yerushalmi, Ryan Woods, Peter M Ravdin, Malcolm M Hayes, Karen A Gelmon

    Résumé Résumé Plan Plan  
• • ·Ewing’s sarcoma

    Page :184-192

    Naomi J Balamuth, Richard B Womer

    Résumé Résumé Plan Plan  
• • ·The metabolic syndrome in cancer survivors

    Page :193-203

    Esther C de Haas, Sjoukje F Oosting, Joop D Lefrandt, Bruce HR Wolffenbuttel, Dirk Th Sleijfer, Jourik A Gietema

    Résumé Résumé Plan Plan  
• • ·Teleoncology: current and future applications for improving cancer care globally

    Page :204-210

    Ribhi Hazin, Ibrahim Qaddoumi

    Résumé Résumé Plan Plan